Modality
ASO
MOA
USP1i
Target
PRMT5
Pathway
Cell Cycle
PsASCLCT2D
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ Mar 2027
Phase 3Current
NCT04846107
2,666 pts·PsA
2019-07→2025-05·Not yet recruiting
NCT04527864
1,846 pts·T2D
2017-02→2027-03·Recruiting
NCT06088039
2,402 pts·PsA
2025-04→2026-02·Active
+1 more trial
7,224 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-05-2310mo agoPh3 Readout· PsA
2025-12-163mo agoPh3 Readout· T2D
2026-02-092mo agoPh3 Readout· PsA
2027-03-0411mo awayPh3 Readout· T2D
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Recruit…
P3
Not yet…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2025-05-23 · 10mo ago
PsA
Ph3 Readout
2025-12-16 · 3mo ago
T2D
Ph3 Readout
2026-02-09 · 2mo ago
PsA
Ph3 Readout
2027-03-04 · 11mo away
T2D
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04846107 | Phase 3 | PsA | Not yet recr... | 2666 | OS |
| NCT04527864 | Phase 3 | T2D | Recruiting | 1846 | BodyWt |
| NCT06088039 | Phase 3 | PsA | Active | 2402 | UPDRS |
| NCT06192227 | Phase 3 | T2D | Recruiting | 310 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |